Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-12

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective is to study the phenotypic, functional and metabolomic characteristics of neutrophils circulating subpopulations in lung cancer patients, and to compare them to a control group of healthy volunteers. A blood sample will be taken before the first treatment session for the lung cancer patient and a second blood sample will be taken during the first evaluation visit.

The investigators hypothesize that there may be different circulating neutrophil subpopulations in patients with metastatic non-small cell lung cancer (NSCLC) involved in tumor progression and resistance to immunotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Circulating Tumor Cells in Lung Cancer Screening

NCT02500693

Lung Neoplasms Pulmonary Disease, Chronic Obstructive

COMPLETED NA

The Role of Interventional Pulmonology, Microbiota and Immune Response in the Patient With Lung Cancer

NCT05164445

Lung Cancer

COMPLETED NA

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

NCT02380196

Non-small Cell Lung Cancer (NSCLC)

COMPLETED

A Study in Non-Small Cell Lung Cancer

NCT07174388

Non Small Cell Lung Cancer

RECRUITING

Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer

NCT04063501

Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immune checkpoint inhibitors (ICI) have been shown to be effective in metastatic lung cancer. Unfortunately, 80% of patients do not respond and show rapid disease progression. Identifying predictive biomarkers of response is essential for early adaptation of management. Circulating lymphocytes and neutrophils represent a biomarker (NLR), predictive of immunotherapy response, in particular via the measurement of the neutrophils /lymphocyte ratio. Some preclinical work suggests a role for circulating neutrophil subpopulations like MDSC (myeloid derived suppressor cells) in ICI resistance. Certain circulating neutrophil subpopulations are thought to promote tumor progression, angiogenesis and metastasis with immunosuppressive activity. Identifying these pro-tumor subpopulations could predict the response to ICI and could be a potential therapeutic target. Our goal is to characterize the circulating neutrophil subpopulations of lung cancer patients and correlate these characteristics with response and survival phenotypically and functionally.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung cancer

Metastatic, with complete mutational status, without anterior treatment

Extra blood tubes

Intervention Type OTHER

Extra blood tubes

Chronic obstructive pulmonary disease (COPD)

Diagnosis of post-smoking COPD (without diagnosis of CP)

Extra blood tubes

Intervention Type OTHER

Extra blood tubes

Healthy volunteers

Healthy volunteers (based on biological and clinical data already available from the partner)

Extra blood tubes

Intervention Type OTHER

Extra blood tubes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extra blood tubes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years,
* male or female,
* affiliated with a Health Insurance,

\- Diagnosis of metastatic stage lung cancer with mutation status, naïve treatment

\- Diagnosis of COPD post-smoking

Exclusion Criteria

* Tuberculosis or other acute or chronic bacterial infections
* Chronic progressive viral infections (Hepatitis B and C, HIV)
* Previous or ongoing chemotherapy
* Impossibility of giving the subject informed information.
* Opposition to the research.
* Participation in another research study with an exclusion period still in progress at pre-inclusion (possible inclusion in an observational study)
* Vulnerable individual (pregnant, parturient or breastfeeding woman), persons under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision)
* Patients benefiting from the AME

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No